IP Library › Granted Patent US 11,298,339
Granted Patent B2
US 11,298,339 · App. 16/624,050 · Granted Apr 12, 2022

Bisdiazabicyclo compound for treatment and/or prevention of hepatitis virus-related diseases or disorders

Inventors: Yifan Zhai (Guangzhou, CN); Xiaoyong Zhang (Guangzhou, CN); Jinlin Hou (Guangzhou, CN); Dajun Yang (Taizhou, CN)
Assignees: JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.; HEALTHQUEST PHARMA INC.
A61K31/407A61K47/54A61K47/55A61P31/20
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,298,339
App. No.
16/624,050
Granted
Apr 12, 2022
Kind
B2
Abstract

Disclosed are a bisdiazabicyclo compound for treating and/or preventing hepatitis virus-related diseases or disorders, a method for treating and/or preventing hepatitis virus-related diseases or disorders by using the bisdiazabicyclo compound, and a use of the bisdiazabicyclo compound in the preparation of a drug for treating and/or preventing hepatitis virus-related diseases or disorders, and/or eliminating or mitigating hepatitis virus-related diseases or disorders.

Claims (8)

1. A method of using a compound for treatment of a disease or disorder associated with a hepatitis virus, wherein the method comprises administering a therapeutically effective amount of the compound to a patient having the disease or disorder associated with a hepatitis virus, and the compound is a bisdiazabicyclo compound or a pharmaceutically acceptable salt thereof,

wherein the disease or disorder associated with hepatitis virus is hepatitis A, hepatitis B, hepatitis C, or liver cirrhosis, and

the compound is

2. The method according to claim 1 , wherein the compound is

3. The method according to claim 1 , wherein the compound treats the disease or disorder associated with hepatitis virus by modulating an immune response.

4. The method according to claim 1 , wherein the method comprises using the compound in combination with a drug known to treat HBV.

5. A method of treating a patient having hepatitis B, comprising administering to the patient a therapeutically effective amount of a compound, wherein the compound is

or a pharmaceutically acceptable salt thereof.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2020
From: YANG, DAJUN
To: JIANGSU ASCENTAGE BIOMED DEVELOPMENT INC.
Reel/Frame 052137/0847 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 17, 2020
From: ZHAI, YIFAN; ZHANG, XIAOYONG; HOU, JINLIN
To: HEALTHQUEST PHARMA INC.
Reel/Frame 052137/0892 →
Priority Claims (1)
CN 201711193388.1 · Nov 24, 2017 · national
Continuity (1)
Related Publication 20210290594A1 · Sep 23, 2021